# 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment

> **NCT00004239** · PHASE1 · TERMINATED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 10 (actual)

## Conditions studied

- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Compound 506U78

## Key facts

- **NCT ID:** NCT00004239
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1999-12
- **Primary completion:** 2002-01
- **Final completion:** 2002-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** poor accrual
- **Last updated:** 2016-07-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004239, "506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00004239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*